Related Experiment Video
Updated: Oct 2, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
Published on: August 28, 2018
Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease
Mingxing Li1,2, Kai Guo2, Xuansheng Huang2
1Division of Cardiology, Huiqiao Medical Centre, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Insights
Galectin-3 (Gal-3) levels are higher in patients with coronary artery disease (CAD) and correlate with disease severity. Elevated Gal-3 predicts major adverse cardiac events (MACEs) in Acute Coronary Syndrome (ACS) patients, suggesting its prognostic value.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- The association between galectin-3 (Gal-3) and coronary artery disease (CAD) requires further clarification.
- Gal-3 is a protein implicated in various cardiovascular processes.
Purpose of the Study:
- To investigate the relationship between serum Gal-3 levels and the presence and severity of CAD.
- To assess Gal-3 as a predictor of adverse outcomes in CAD patients, particularly those with Acute Coronary Syndrome (ACS).
Main Methods:
- Serum Gal-3 levels were measured in 331 CAD patients and 62 controls.
- Comparisons were made between non-CAD and CAD groups, stable CAD and ACS subgroups, and based on SYNTAX scores (SSs).
- One-year Major Adverse Cardiac Events (MACEs) rates were analyzed in ACS patients stratified by Gal-3 levels.
Main Results:
- Serum Gal-3 was significantly elevated in CAD patients compared to controls (3.89 vs. 2.07 ng/ml, P < 0.001).
- Gal-3 levels were higher in ACS subgroups (NSTE-ACS and STEMI) compared to stable CAD.
- Gal-3 was an independent predictor of ACS (OR=1.131) and high SS (OR=1.030).
- ACS patients with Gal-3 above the median had higher MACE rates; Gal-3 remained an independent risk factor for MACEs (6% higher incidence per 1 ng/ml increment).
Conclusions:
- Galectin-3 levels correlate with CAD presence, stability, and complexity.
- Serum Gal-3 shows potential as a valuable biomarker for predicting mid-term prognosis in ACS patients.
Background:
The relationship between galectin-3 (Gal-3) and coronary artery disease (CAD) has not been fully elucidated.
Aim:
This study aimed to determine the relationship between the presence and severity of CAD and serum Gal-3 levels.
Patients And Methods:
Three-hundred thirty-one consecutive CAD patients were enrolled as the study group. An additional 62 patients without CAD were enrolled as the control group. Serum Gal-3 levels were separately compared between the non-CAD and CAD groups, among the stable CAD and Acute coronary syndrome (ACS) groups, and between CAD patients with low and high SYNTAX scores (SSs). The 1-year cumulative rate of major adverse cardiac events (MACEs) was also compared among ACS patients by Gal-3 levels.
Results:
Serum Gal-3 was significantly higher in the CAD group than in the non-CAD group 3.89 (0.16-63.67) vs. 2.07 (0.23-9.38) ng/ml, P < 0.001. Furthermore, serum Gal-3 was significantly higher in the non-ST-segment elevation ACS (NSTE-ACS) group than that in the stable CAD group, 4.72 (1.0-16.14) vs. 2.23 (0.65-23.8) ng/ml, P = 0.04 and higher in the ST-segment elevation myocardial infarction (STEMI) group than that in the stable CAD group 7.87 (0.59-63.67) vs. 2.23 (0.65-23.8) ng/ml, P < 0.001. Serum Gal-3 level was an independent predictor of ACS compared with stable CAD group (OR = 1.131, 95% CI: 1.051-1.217, P = 0.001) as well as high SS (OR = 1.030, 95% CI: 1.021-1.047, P = 0.038) after adjust other confounding risk factors. Acute coronary syndrome patients with Gal-3 levels above the median (gal-3 = 4.78 ng/ml) showed a higher cumulative MACE rate than those with Gal-3 levels below the median. After adjusting other confounding risk factors, Gal-3 remained an independent risk factor for the cumulative rate of MACEs in ACS patients (6% higher rate of MACEs incidence per 1 ng/ml increment of Gal-3).
Conclusion:
Galectin-3 correlated with the presence of CAD as well as coronary stability and complexity. Galectin-3 may be valuable in predicting mid-term prognosis in ACS patients.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Angina III: Clinical Manifestations and Assessment
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology

